MulberrinCAS# 62949-79-5 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 62949-79-5 | SDF | Download SDF |
| PubChem ID | 5481958 | Appearance | Yellow powder |
| Formula | C25H26O6 | M.Wt | 422.5 |
| Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
| Solubility | DMSO : 100 mg/mL (236.70 mM; Need ultrasonic) | ||
| Chemical Name | 2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-3,8-bis(3-methylbut-2-enyl)chromen-4-one | ||
| SMILES | CC(=CCC1=C(C=C(C2=C1OC(=C(C2=O)CC=C(C)C)C3=C(C=C(C=C3)O)O)O)O)C | ||
| Standard InChIKey | UWQYBLOHTQWSQD-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C25H26O6/c1-13(2)5-8-17-20(28)12-21(29)22-23(30)18(9-6-14(3)4)24(31-25(17)22)16-10-7-15(26)11-19(16)27/h5-7,10-12,26-29H,8-9H2,1-4H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Mulberrin is a strong inhibitor of organic anion-transporting polypeptide 2B1 (OATP2B1)-mediated estrone-3-sulfate (E3S) uptake with an IC50 value being 1.8 ±1.5 μM; it also as HIV-1 reverse transcriptase inhibitor. Mulberrin has significantly reduced role on blood sugar of type II diabetes model of rats. |
| Targets | HIV | OATP2B1 |
| In vitro | Virtual screening of Indonesian herbal database as HIV-1 reverse transcriptase inhibitor.[Pubmed: 23275721]Bioinformation. 2012;8(24):1206-10.HIV-1 (Human immunodeficiency virus type 1) is a member of retrovirus family that could infect human and causing AIDS disease. AIDS epidemic is one of most destructive diseases in modern era. There were more than 33 million people infected by HIV until 2010. Various studies have been widely employed to design drugs that target the essential enzymes of HIV-1 that is, reverse transcriptase, protease and integrase.
|
| In vivo | Experimental study of mulberrin on blood glucose of Type Ⅱ diabetes model rats.[Reference: WebLink]Journal of Traditional Chinese Medicine University of Hunan, 2011, 31(5):26-8.The experiment had investigated the results by using Mulberrin on blood glucose,insulin,glycated hemoglobin,glucose tolerance of Type II diabetes model rats. |
| Kinase Assay | Identification of natural products as modulators of OATP2B1 using LC-MS/MS to quantify OATP-mediated uptake.[Pubmed: 25858254 ]Pharm Biol. 2016;54(2):293-302.Organic anion-transporting polypeptide 2B1 (OATP2B1) which is highly expressed in enterocytes and hepatocytes could be a key determinant for the intestinal absorption and hepatic uptake of its substrate drugs. Natural products are commonly used in traditional Chinese medicine, foods, and beverages.
The objective of this study is to determine the OATP2B1-mediated drug interactions that could occur between natural products and OATP2B1 substrate drugs.
|
Mulberrin Dilution Calculator
Mulberrin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.3669 mL | 11.8343 mL | 23.6686 mL | 47.3373 mL | 59.1716 mL |
| 5 mM | 0.4734 mL | 2.3669 mL | 4.7337 mL | 9.4675 mL | 11.8343 mL |
| 10 mM | 0.2367 mL | 1.1834 mL | 2.3669 mL | 4.7337 mL | 5.9172 mL |
| 50 mM | 0.0473 mL | 0.2367 mL | 0.4734 mL | 0.9467 mL | 1.1834 mL |
| 100 mM | 0.0237 mL | 0.1183 mL | 0.2367 mL | 0.4734 mL | 0.5917 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Kuwanon A
Catalog No.:BCN2944
CAS No.:62949-77-3
- H-D-Pro-NH2
Catalog No.:BCC3024
CAS No.:62937-45-5
- Procaterol hydrochloride
Catalog No.:BCC6937
CAS No.:62929-91-3
- Heptanal oxime
Catalog No.:BCN2267
CAS No.:629-31-2
- Cefoperazone
Catalog No.:BCC3748
CAS No.:62893-19-0
- Hecubine
Catalog No.:BCN7467
CAS No.:62874-52-6
- TP 003
Catalog No.:BCC6169
CAS No.:628690-75-5
- Senampeline B
Catalog No.:BCN2031
CAS No.:62860-52-0
- 2-Amino-6-nitrobenzothiazole
Catalog No.:BCC8544
CAS No.:6285-57-0
- Senampeline E
Catalog No.:BCN2032
CAS No.:71075-42-8
- Meglumine
Catalog No.:BCC4795
CAS No.:6284-40-8
- Jolkinol A
Catalog No.:BCN3778
CAS No.:62820-11-5
- Morusinol
Catalog No.:BCN4168
CAS No.:62949-93-3
- 6-Methoxy-4-methylcoumarin
Catalog No.:BCN6537
CAS No.:6295-35-8
- (2-Benzothiazolylthio)acetic acid
Catalog No.:BCC8387
CAS No.:6295-57-4
- Gomisin F
Catalog No.:BCN3625
CAS No.:62956-47-2
- Gomisin G
Catalog No.:BCN2269
CAS No.:62956-48-3
- Gnetucleistol D
Catalog No.:BCN3400
CAS No.:629643-26-1
- Boc-Tle-OH
Catalog No.:BCC3343
CAS No.:62965-35-9
- XL335
Catalog No.:BCC4501
CAS No.:629664-81-9
- 6-Aminoquinoxaline
Catalog No.:BCC8767
CAS No.:6298-37-9
- Staurosporine
Catalog No.:BCC3612
CAS No.:62996-74-1
- Androstenedione
Catalog No.:BCC8296
CAS No.:63-05-8
- Primaquine Diphosphate
Catalog No.:BCC4706
CAS No.:63-45-6
Mulberrin (Mul) reduces spinal cord injury (SCI)-induced apoptosis, inflammation and oxidative stress in rats via miroRNA-337 by targeting Nrf-2.[Pubmed:30257365]
Biomed Pharmacother. 2018 Nov;107:1480-1487.
Spinal cord injury (SCI) is a major reason of paralysis, disability and even death in severe cases. Mulberrin (Mul) is a major compound of ramulus mori and turned out that it has potent ability on tyrosinase inhibition. Ramulus mori has been reported to possess anti-inflammation, anti-oxidative stress and anti-apoptosis effects. However, the effects of Mul on SCI progression and the underlying molecular mechanism have never been elucidated before. Here, we established a SCI rat model, which subsequently received Mul treatment. The findings showed that Mul treatment improved the functional recovery of SCI rats, along with reduced spinal cord water contents and myeloperoxidase (MPO) activity. SCI-induced apoptosis was attenuated by Mul, as evidenced by the reduced TUNEL-positive cells, and the decreased pro-apoptotic signals expressions, while increased anti-apoptotic molecule. Further, Mul inhibited inflammatory response in the spinal cord tissues of SCI rats through inactivating nuclear factor-kappa B (NF-kappaB) pathway. Oxidative stress was also decreased by Mul treatment in SCI mice, associated with the up-regulation of heme oxygenase-1 (HO-1)/nuclear factor E2-related factor 2 (HO-1/Nrf-2) pathway. Significantly, SCI rats showed high expression of miR-337 in spinal cord tissue samples. Astrocytes (AST) stimulated by LPS also had higher expression of miR-337. Nrf-2 was found to be a direct target for miR-337. Over-expressing miR-337 markedly reduced Nrf-2 expression in AST, whereas inhibiting miR-337, Nrf-2 expressions were significantly increased. In vitro, AST transfected with miR-337 inhibitor showed attenuated inflammation, apoptosis and oxidative stress in LPS-treated AST, which was, intriguingly, abolished by Nrf-2 knockdown. Together, the findings above indicated that Mul could attenuate SCI by reducing miR-337 expressions to reduce apoptosis, inflammation and oxidative stress via regulating Nrf-2.
